Program
greziprubart
Also written as “STSA-1002 injection”, “STSA-1002 Injection” and “STSA-1002 subcutaneous injection”.
Its studies are mostly in Respiratory Distress Syndrome · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, led by Staidson (Beijing) Biopharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals | 71 open or running | phase 3since Sep 28, 2025 | Aug 19, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 19, 2021First study: phase 1 study in HealthyFirst studyNCT05032144 · 40 enrolled · United States
- Dec 8, 2021Phase 1 study in HealthyNCT05166837 · 52 enrolled · China
- Aug 1, 2022Phase 1 study in Healthy SubjectNCT05497635 · 26 enrolled · China
- Sep 26, 2022Phase 1 study in Healthy SubjectNCT05559125 · 50 enrolled · China
- Dec 23, 2022Phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT05702983 · 20 enrolled · United States
- Sep 8, 2023Phase 2 study in Respiratory Distress SyndromeNCT06038916 · 47 enrolled · China
- Sep 28, 2025Phase 3 study in Respiratory Distress SyndromeNCT07208591 · 406 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07208591Respiratory Distress Syndrome · China | 3 | Recruiting | Jul 2026 | 406 |
| NCT06038916Respiratory Distress Syndrome · China | 2 | Completed | Mar 20, 2025 | 47 |
| NCT05702983Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States | 1 | Completed | Apr 11, 2023 | 20 |
| NCT05559125Healthy Subject · China | 1 | Terminated | Mar 26, 2024 | 50 |
| NCT05497635Healthy Subject · China | 1 | Completed | Apr 6, 2023 | 26 |
| NCT05166837Healthy · China | 1 | Completed | Jan 12, 2023 | 52 |
| NCT05032144Healthy · United States | 1 | Completed | Mar 31, 2022 | 40 |
How it is read
Names in the registry
- “STSA-1002 injection”, 11 entries
- “STSA-1002 Injection”, 3 entries
- “STSA-1002 subcutaneous injection”, 2 entries
Conditions, from the studies’ own filings
- Respiratory Distress Syndrome, 2 studies
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.